ATC Group: C01AA05 Digoxin

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C01AA05 in the ATC hierarchy

Level	Code	Title
`1`	C	Cardiovascular system
`2`	C01	Cardiac therapy
`3`	C01A	Cardiac glycosides
`4`	C01AA	Digitalis glycosides
`5`	C01AA05	Digoxin

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Code	Route	Amount	Notes
ORAL	Oral	0.25 mg
PAREN	Parenteral	0.25 mg

Active ingredients in C01AA05

Active Ingredient
Digoxin
Digoxin increases contractility of the myocardium by direct activity. The primary action of digoxin is specifically to inhibit adenosine triphosphatase, and thus sodium-potassium (Na+ - K+) exchange activity, the altered ionic distribution across the membrane resulting in an augmented calcium ion influx and thus an increase in the availability of calcium at the time of excitation-contraction coupling. The potency of digoxin may therefore appear considerably enhanced when the extracellular potassium concentration is low, with hyperkalaemia having the opposite effect.

Related product monographs

Document	Type	Information Source
Lanoxin 125 Tablets	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)
LANOXIN Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)
LANOXIN Tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)